Comparing New Injection to Standard for Wet AMD
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a new investigational injection, QL1207H, against an already approved drug (aflibercept) for people with wet age-related macular degeneration, a condition that causes rapid central vision loss. The goal is to see if the new injection works as well or better at stopping further vision loss and possibly improving sight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 50 years old.
- You must have wet age-related macular degeneration that is actively leaking fluid in the center of your vision in the study eye.
- Your vision in the study eye must be moderately to severely reduced (but not completely blind).
- You must not have scarring, shrinkage, or severe bleeding in the center of the retina in the study eye.
- You must not have other causes for your condition, such as very high nearsightedness or severe glaucoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called RBS-001 compared to the standard treatment Eylea for wet age-related macular degeneration (AMD). The goal is to see if the new drug is as safe and effective at improving vision by reducing fluid and blood vessel growth in the eye.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This trial tests an experimental eye injection called GB10 for wet AMD. It is for people who have active leaking blood vessels in the eye and whose vision is between 20/32 and 20/320.
This study tests a combination of standard eye injections and laser treatment for wet age-related macular degeneration, a condition where abnormal blood vessels leak fluid and harm vision. It aims to see if this combined approach is safe and effective, potentially reducing the number of injections needed.
This trial tests a new CRISPR-based gene therapy injected into the eye to treat wet age-related macular degeneration (AMD). It aims to stop the growth of abnormal blood vessels that damage your vision.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.